Clinical Trial Detail

NCT ID NCT02596971
Title A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Atezolizumab + Bendamustine + Obinutuzumab

Atezolizumab + Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate

Atezolizumab + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate

Age Groups: adult senior

No variant requirements are available.